Publications

Pregnancy Outcomes and Postpartum Relapse Rates in Women with Rrms Treated with Alemtuzumab in the Phase 2 and 3 Clinical Development Program over 16 Years

AuthID
P-00S-8D8

Author(s)

Oh, J

Achiron, A

Celius, EG

Chambers, C

Derwenskus, J

Devonshire, V

Hellwig, K

Hutton, GJ

McCombe, P

Moore, M

Rog, D

Schneider, JR

Simm, RF

Sousa, L

Vincent, SG

Chung, LK

Daizadeh, N

Mitchell, C

Compston, DAS

Group Author(s)

CAMMS223; CARE-MS I; CARE-MS II; CAMMS03409; TOPAZ Investigators

Document Type

Article

Year published

2020

Published

in MULTIPLE SCLEROSIS AND RELATED DISORDERS, ISSN: 2211-0348

Volume: 43

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.msard.2020.102146

Pubmed: 32498033

Scopus: 2-s2.0-85085609860

Wos: WOS:000548665900008

Source Identifiers

ISSN: 2211-0348

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Pregnancy Outcomes and Postpartum Relapse Rates in Women with Rrms Treated with Alemtuzumab in the Phase 2 and 3 Clinical Development Program over 16 Years

Useful Links

Get Help

Federated Authentication (Click on the image)

Pregnancy Outcomes and Postpartum Relapse Rates in Women with Rrms Treated with Alemtuzumab in the Phase 2 and 3 Clinical Development Program over 16 Years

Useful Links

Get Help